¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumor lethal dose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • virilizing tumor
    ³²¼ºÈ­Á¾¾ç
  • Wilms¡¯ tumor
    ºô¸§½ºÁ¾¾ç
  • acceptable daily dose
    ÀÏÀÏÇã¿ë·®
  • average dose
    1. Æò±Õ¿ë·® 2. Æò±Õ¼±·®
  • air dose
    °ø±â¼±·®
  • absorbed dose
    Èí¼ö¼±·®
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • absorbed dose rate
    Èí¼ö¼±·®·ü
  • biologically effective dose
    »ý¹°ÇÐÀûÀ¯È¿¼±·®
  • booster dose
    1. Ãß°¡¿ë·® 2. Ãß°¡Á¢Á¾·®
  • collective effective dose
    Áý´ÜÀ¯È¿¼±·®
  • committed dose equivalent
    ¿¹Å¹¼±·®ÇØ´ç·®
  • committed effective dose
    ¿¹Å¹À¯È¿¼±·®
  • cumulative dose
    1. ´©Àû¿ë·® 2. ´©Àû¼±·®
  • curative dose
    1. Ä¡À¯¿ë·® 2. Ä¡À¯¼±·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • solid tumor
    °íÇüÁ¾¾ç
  • solid-cystic tumor
    °íü³¶¼ºÁ¾¾ç
  • stromal tumor
    ¼º²ö°£ÁúÁ¾¾ç, ³­¼Ò¹öÆÀÁúÁ¾¾ç
  • tumor stain
    Á¾¾çÁ¶¿µ
  • tumor cell survival
    Á¾¾ç¼¼Æ÷»ýÁ¸
  • tumor
    Á¾¾ç
  • teratodermoid tumor
    ±âÇüÀ¯ÇÇÁ¾
  • teratoid tumor
    ±âÇüÁ¾
  • tridermic tumor
    »ï¹è¿±Á¾¾ç
  • trophoblastic tumor
    ¿µ¾ç¸·Á¾¾ç
  • virilizing tumor
    ³²¼ºÈ­Á¾¾ç
  • virus-induced tumor
    ¹ÙÀÌ·¯½ºÀ¯¹ßÁ¾¾ç
  • Wilms' tumor
    Àª¸§ÁîÁ¾¾ç
  • absorbed dose
    Èí¼ö¼±·®
  • absorbed dose rate
    Èí¼ö¼±·®·ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • adenomatoid tumor
    ¼±¾çÁ¾¾ç
  • adenomatoid tumor
    ¼±Á¾¾çÁ¾¾ç(àÍðþåÆðþåË), À¯¼±Á¾Á¾¾ç(×¾àÍðþðþåË)
  • adenomatoid tumor, tubal
    ¼±Á¾¾çÁ¾¾ç(àÍðþåÆðþåË), ³­°ü(Ñëη)ÀÇ
  • adrenal medulla,tumor of chemoreceptor system
    È­Çмö¿ëü°è Á¾¾ç(ûùùÊáôé»ô÷ͧ ðþåË)
  • adrenal rest tumor
    ºÎ½ÅÀÜÀ¯Á¾¾ç
  • adrenal tumor
    ºÎ½ÅÁ¾¾ç(ÜùãìðþåË).
  • alpha cell tumor
    ¾ËÆÄ ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • amyloid tumor
    ¾Æ¹Ð·ÎÀ̵åÁ¾¾ç.
  • angiomatoid tumor
    À¯Ç÷°üÁ¾ Á¾¾ç, Ç÷°üÁ¾¾ç Á¾¾ç
  • antigen, tumor-specific
    Á¾¾çƯÀÌÇ׿ø
  • antigen, tumor-specific transplantation
    Á¾¾çƯÀÌ À̽ÄÇ׿ø
  • antigen,fetal tumor-associated
    žÆÁ¾¾ç °ü·Ã¼º(÷Ãä®ðþåË Î¼Ö¤àõ)
  • antigen,tumor-specific transplantation
    Á¾¾ç ƯÀÌÀ̽Ä(ðþåË ÷åì¶ì¹ãÕ)
  • appendigeal tumor
    ºÎ¼Ó±â Á¾¾ç(ðþåË)
  • genitourinary tumor
    ºñ´¢»ý½Ä±â Á¾¾ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • carcinoma dose
    Á¦¾Ï·®.
  • central axis depth dose
    Áß½ÉÃà½ÉºÎ¼±·®
  • child dose
    ¼Ò¾Æ¾à¿ë·®(¡­å·éÄåÖ).
  • collective effective dose
    Áý´ÜÀ¯È¿¼±·®
  • collective equivalent dose
    Áý´Ü´ç·®¼±·®
  • committed dose equivalent
    ¿¹Å¹¼±·®´ç·®
  • committed effective dose
    ¿¹Å¹À¯È¿¼±·®
  • committed effective dose equivalent
    ¿¹Å¹À¯È¿¼±·®´ç·®
  • committed equivalent dose
    ¿¹Å¹´ç·®¼±·®
  • continuous low dose rate irradiation
    Àú¼±·®À²¿¬¼Ó¹æ»ç¼±Á¶»ç
  • cumulative absorbed dose
    ´©Àû (Èí¼ö) ¼±·®
  • curative dose
    ġȿ·®(ö½üùåÖ).
  • curative dose
    Ä¡À¯¼±·®
  • curative dose
    Ä¡À¯·®(Ä¡À¯¾ç). Ä¡·á¼±·®
  • depth dose
    ½ÉºÎ¼±·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
DL danger list; De Lee [catheter]; deep lobe; developmental level; difference limen; diffusion lung [ca...
ELD egg lethal dose
LD50 median lethal dose
LD50/30 a dose that is lethal for 50% of test subjects within 30 days
LD100 lethal dose in all exposed subjects
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
PLDR potentially lethal damage
SLD sub-lethal damage
BMD Benchmark dose
BED Biologically Effective Dose
CTDI Computed Tomography Dose Index
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • permissible dose
    Çã¿ë·®
  • radiation dose
    ¼±·®
    ¹°ÁúÀ̳ª Á¶Á÷ ¶Ç´Â Àü½Å ¹× ±¹ºÎ µîÀÌ ¹ÞÀº ¹æ»ç¼±ÀÇ ¾ç. Á¶»ç ½Ã°£ ÁßÀÇ ¹æ»ç¼± ¿¡³ÊÁöÀÇ Èí¼ö·®¿¡ ÇØ´çÇÑ´Ù.
  • skin dose
    ÇǺΠ¼±·®
  • therapeutic dose
    Ä¡·á·®, Ä¡·á ¿ë·®
  • total dose
    Àü·®, ÃѼ±·®
  • acoustic tumor
    û½Å°æ Á¾¾ç
    Á¦ 8 ½Å°æ¿¡¼­ »ý±ä ¾ç¼º Á¾¾ç.
  • ACTH-secreting tumor
    ACTH-ºÐºñ Á¾¾ç
    µ¿ÀǾî=corticotro
  • adenomatoid tumor
    ¼± Á¾¾ç Á¾¾ç, À¯¼±Á¾ Á¾¾ç
    ¼ºÀå ¼Óµµ°¡ ´À¸° ÀÛÀº °áÀýÇüÀÇ ¾ç¼º Á¾¾çÀ̳ª ¶§·Î´Â ¼ö cm±îÁö µÉ ¼ö ÀÖ´Ù. ÀÌ Á¾¾çÀº ºÎ°íȯ Á¾¾ç Áß °¡Àå ÈçÇÏ¸ç ¿©ÀÚ¿¡¼­µµ Àڱà ¶Ç´Â ¼ö¶õ°üÀÇ À帷Ãþ¿¡ ¹ß»ýÇÒ ¼ö ÀÖ´Ù.
  • adrenal cortex tumor
    ºÎ½Å ÇÇÁú Á¾¾ç
  • amelanotic tumor
    ¹«¸á¶ó´Ñ Á¾¾ç
  • benign giant cell tumor
    ¾ç¼º °Å´ë¼¼Æ÷ Á¾¾ç
    1. °ñÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. °ñÀÇ ¾ç¼º Á¾¾çÀÇ Çϳª·Î ³ë¾àÀÚ¿¡°Ô ¸¹À¸¸ç ¹ß»ý ºÎÀ§´Â Àå°ü°ñÀÇ °ñ´Ü¿¡ ¸¹ÀÌ ³ªÅ¸³­´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¿øÇü, ¹æÃßÇüÀÌ ÀÖ´Ù. ¼¼Æ÷ »çÀÌ¿¡ ÆÄ°ñ¼¼Æ÷¿Í À¯»çÇÑ °Å´ë¼¼Æ÷°¡ È¥ÀçÇÑ´Ù. 2. °ÇÃÊÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. º»·¡ Á¾¾çÀÌ ¾Æ´Ï¸ç, °áÁ¤¼º °ÇÃÊ¿°À» °¡¸®Å°¸ç °ÇÃÊÀÇ ¼¶À¯¼º Á¶Á÷±¸Á¾¿¡ Æ÷ÇԵȴÙ.
  • benign melanocytic tumor
    ¾ç¼º ¸á¶ó´Ñ ¼¼Æ÷Á¾
  • benign vascular tumor
    ¾ç¼º Ç÷°üÁ¾
  • beta cell tumor
    º£Å¸ ¼¼Æ÷Á¾
  • beta-cell tumor
    º£Å¸ ¼¼Æ÷ Á¾¾ç
    µµ¼¼Æ÷ Á¾¾ç Áß °¡Àå ÈçÇÑ Áúº´À¸·Î Àν¶¸° °ú´Ù ºÐºñ°¡ ÀϾ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
dose-response relationship, radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.
(12 Dec 1998)
immunologic high dose tolerance Induction of tolerance by exposure to large amounts of protein antigens.
(05 Mar 2000)
initial dose A comparatively large dose given at the beginning of treatment to get the patient under the influence of the drug.
Synonym: loading dose.
(05 Mar 2000)
integral dose The total energy absorbed by the body, the product of the mass of tissue irradiated and the absorbed dose; unit, the gram rad.
(05 Mar 2000)
optimum dose The dose of a drug or radiation that will produce the desired effect with minimum likelihood of undesirable symptoms.
(05 Mar 2000)
therapeutic dose The quantity of any substance required to effect the cure of a disease or that will correct the manifestations of a deficiency of a particular factor in the diet, effective dose used with therapeutically applied compounds.
Synonym: therapeutic dose.
(05 Mar 2000)
effective dose The dose that produces the desired effect; when followed by a subscript (generally "ED50"), it denotes the dose having such an effect on a certain percentage (e.g., 50%) of the test animals; ED50 is the median effective dose, in radiation protection, the sum of the equivalent doses in all tissues and organs of the body weighted for tissue effects of radiation. The unit of effective dose is the sievert (Sv), epilation dose, the minimum amount of radiation sufficient to produce hair loss, usually in 10 to 14 days.
(05 Mar 2000)
tissue culture infectious dose The quantity of a cytopathogenic agent, such as a virus, that will produce a cytopathic effect in 50% of the cultures inoculated.
(05 Mar 2000)
tolerance dose The largest dose of a remedy that can be accepted without the production of injurious symptoms.
(05 Mar 2000)
equianalgesic dose The qualitative ratio between actual milligram potency of comparable analgesics required to achieve the equivalent therapeutic effect.
(05 Mar 2000)
equivalent dose In radiation protection, the absorbed dose averaged over a tissue or organ and weighted for the quality of the radiation of interest. The unit of equivalent dose is the sievert.
(05 Mar 2000)
erythema dose The minimum amount of X-rays or other form of radiation sufficient to produce erythema; historically, this dose was indicated by the Sabouraud meter as the B tint, the Holzknecht as 5(5H), the Hampson as 4, and the Kienbock as 10.
(05 Mar 2000)
exit dose The exposure dose of radiation leaving a body opposite the portal of entry.
(05 Mar 2000)
exposure dose The radiation dose, expressed in roentgens, delivered at a point in free air.
Synonym: air dose.
(05 Mar 2000)
unit dose Occurring in or using a single dose, seen as a standard of measurement.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á